Stock Track | BioMarin Pharmaceutical (BMRN) Soars 10.52% in Pre-Market on Record Q4 Results, Strong 2025 Outlook

Stock Track

20 Feb

BioMarin Pharmaceutical Inc. (BMRN) saw its stock surge 10.52% in pre-market trading on Thursday following the company's exceptional fourth-quarter 2024 earnings report and robust guidance for 2025.

BioMarin reported record financial performance for the fourth quarter and full-year 2024. Total revenue grew 18% year-over-year to $2.85 billion in 2024, with Q4 revenue increasing 16% to $747 million. The company's flagship product, VOXZOGO for achondroplasia, saw impressive growth of 56% in 2024, reaching $735 million in revenue. Additionally, BioMarin's Enzyme Therapy portfolio exceeded $1.9 billion in revenue, reflecting a 12% increase from 2023. Profitability metrics were equally impressive, with non-GAAP operating margins expanding by 9.2 percentage points to 28.6% for the full year, and non-GAAP diluted EPS increasing 69% to $3.52. Operating cash flow for 2024 surged 260% to $573 million, showcasing the company's robust cash generation capabilities.

BioMarin provided an optimistic outlook for 2025, forecasting total revenue between $3.1 billion and $3.2 billion, representing a 10% growth rate. The company expects non-GAAP operating margins to improve further, ranging between 32% and 33%, while non-GAAP diluted EPS is projected to be in the range of $4.20 to $4.40 per share. This guidance reflects BioMarin's confidence in sustaining strong momentum and growth across its portfolio, particularly in its lead products and pipeline candidates.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1126423815"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126423815\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1126423815?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 18:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126423815","market":"us","top_or_hot":-1,"title":"Stock Track | BioMarin Pharmaceutical (BMRN) Soars 10.52% in Pre-Market on Record Q4 Results, Strong 2025 Outlook","media":"Stock Track","content":"<p>\nBioMarin Pharmaceutical Inc. (BMRN) saw its stock surge 10.52% in pre-market trading on Thursday following the company's exceptional fourth-quarter 2024 earnings report and robust guidance for 2025.\n</p>\n\n<p>\nBioMarin reported record financial performance for the fourth quarter and full-year 2024. Total revenue grew 18% year-over-year to $2.85 billion in 2024, with Q4 revenue increasing 16% to $747 million. The company's flagship product, VOXZOGO for achondroplasia, saw impressive growth of 56% in 2024, reaching $735 million in revenue. Additionally, BioMarin's Enzyme Therapy portfolio exceeded $1.9 billion in revenue, reflecting a 12% increase from 2023. Profitability metrics were equally impressive, with non-GAAP operating margins expanding by 9.2 percentage points to 28.6% for the full year, and non-GAAP diluted EPS increasing 69% to $3.52. Operating cash flow for 2024 surged 260% to $573 million, showcasing the company's robust cash generation capabilities.\n</p>\n\n<p>\nBioMarin provided an optimistic outlook for 2025, forecasting total revenue between $3.1 billion and $3.2 billion, representing a 10% growth rate. The company expects non-GAAP operating margins to improve further, ranging between 32% and 33%, while non-GAAP diluted EPS is projected to be in the range of $4.20 to $4.40 per share. This guidance reflects BioMarin's confidence in sustaining strong momentum and growth across its portfolio, particularly in its lead products and pipeline candidates.\n</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioMarin Pharmaceutical (BMRN) Soars 10.52% in Pre-Market on Record Q4 Results, Strong 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioMarin Pharmaceutical (BMRN) Soars 10.52% in Pre-Market on Record Q4 Results, Strong 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-20 18:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>\nBioMarin Pharmaceutical Inc. (BMRN) saw its stock surge 10.52% in pre-market trading on Thursday following the company's exceptional fourth-quarter 2024 earnings report and robust guidance for 2025.\n</p>\n\n<p>\nBioMarin reported record financial performance for the fourth quarter and full-year 2024. Total revenue grew 18% year-over-year to $2.85 billion in 2024, with Q4 revenue increasing 16% to $747 million. The company's flagship product, VOXZOGO for achondroplasia, saw impressive growth of 56% in 2024, reaching $735 million in revenue. Additionally, BioMarin's Enzyme Therapy portfolio exceeded $1.9 billion in revenue, reflecting a 12% increase from 2023. Profitability metrics were equally impressive, with non-GAAP operating margins expanding by 9.2 percentage points to 28.6% for the full year, and non-GAAP diluted EPS increasing 69% to $3.52. Operating cash flow for 2024 surged 260% to $573 million, showcasing the company's robust cash generation capabilities.\n</p>\n\n<p>\nBioMarin provided an optimistic outlook for 2025, forecasting total revenue between $3.1 billion and $3.2 billion, representing a 10% growth rate. The company expects non-GAAP operating margins to improve further, ranging between 32% and 33%, while non-GAAP diluted EPS is projected to be in the range of $4.20 to $4.40 per share. This guidance reflects BioMarin's confidence in sustaining strong momentum and growth across its portfolio, particularly in its lead products and pipeline candidates.\n</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMRN","symbol_name":"拜玛林制药","start_time":0,"source_url":"","article_id":"1126423815","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126423815","pubTimestamp":1740046728,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioMarin Pharmaceutical Inc.  saw its stock surge 10.52% in pre-market trading on Thursday following the company's exceptional fourth-quarter 2024 earnings report and robust guidance for 2025.BioMarin provided an optimistic outlook for 2025, forecasting total revenue between $3.1 billion and $3.2 billion, representing a 10% growth rate. The company expects non-GAAP operating margins to improve further, ranging between 32% and 33%, while non-GAAP diluted EPS is projected to be in the range of $4.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMRN":"拜玛林制药"},"translate_title":"股票赛道拜玛林制药(BMRN)盘前飙升10.52%，第四季度业绩创纪录，2025年前景强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":1},"content_text":"BioMarin Pharmaceutical Inc. (BMRN) saw its stock surge 10.52% in pre-market trading on Thursday following the company's exceptional fourth-quarter 2024 earnings report and robust guidance for 2025.\n\n\nBioMarin reported record financial performance for the fourth quarter and full-year 2024. Total revenue grew 18% year-over-year to $2.85 billion in 2024, with Q4 revenue increasing 16% to $747 million. The company's flagship product, VOXZOGO for achondroplasia, saw impressive growth of 56% in 2024, reaching $735 million in revenue. Additionally, BioMarin's Enzyme Therapy portfolio exceeded $1.9 billion in revenue, reflecting a 12% increase from 2023. Profitability metrics were equally impressive, with non-GAAP operating margins expanding by 9.2 percentage points to 28.6% for the full year, and non-GAAP diluted EPS increasing 69% to $3.52. Operating cash flow for 2024 surged 260% to $573 million, showcasing the company's robust cash generation capabilities.\n\n\nBioMarin provided an optimistic outlook for 2025, forecasting total revenue between $3.1 billion and $3.2 billion, representing a 10% growth rate. The company expects non-GAAP operating margins to improve further, ranging between 32% and 33%, while non-GAAP diluted EPS is projected to be in the range of $4.20 to $4.40 per share. This guidance reflects BioMarin's confidence in sustaining strong momentum and growth across its portfolio, particularly in its lead products and pipeline candidates.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}